Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab) ...Middle East

- ATG-037 is Antengene's oral small molecule CD73 inhibitor; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy - The clinical trial collaboration will focus on evaluating ATG-037 as a monotherapy and in combination with KEYTRUDA® for the treatment of locally advanced or metastatic...

Hence then, the article about antengene enters into a global clinical collaboration with msd to evaluate atg 037 cd73 inhibitor in combination with keytruda pembrolizumab was published today ( Tuesday 27/12/2022 - 04:04 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA® (pembrolizumab) )

Also on site :

• 11 Colorado schools receive threats, several on lockdown
• Aurora man arrested on suspicion of starting massive Leetsdale Drive fire
• US Visa Processing Frozen By Trump Administration in 75 Countries